003020.SZ
Hefei Lifeon Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 17.49
−3.64%Sep 18, 2026, 07:51 UTC
Hefei Lifeon Pharmaceutical received acceptance from China's National Medical Products Administration for its clinical trial application for celecoxib and tramadol hydrochloride tablets (acceptance number CYHL2600101).
Source:Aug 3, 2026, 03:44 UTC
Lifang Pharmaceutical announced that its doxazosin mesylate extended-release tablets and azilsartan medoxomil potassium tablets are proposed to be selected in the 12th batch of China's national centralized drug procurement, with the procurement cycle lasting until December 31, 2029.
Source:Jul 9, 2026, 10:37 UTC
Lifang Pharmaceutical announced that 4 of its drug varieties were newly included in the National Essential Drug List (2026 edition).